Timeline Entry
On 12 April 1955, epidemiologist Thomas Francis Jr. announced at the University of Michigan in Ann Arbor that the inactivated poliovirus vaccine developed by Jonas Salk and his University of Pittsburgh team had reduced paralytic polio in the 1954 field trial. Federal licences followed that day. The result supplied the first persuasive population evidence for what became the first licensed polio vaccine, not proof that every dose subsequently manufactured would be safe (Francis and Korns 1955; University of Michigan press release).
The event belongs neither to a lone-inventor story nor to an uncomplicated victory. It joined decades of virology, disability care, public fundraising, school-based research, industrial manufacture, and federal regulation. The same rapid rollout that made prevention possible also exposed a lethal gap between a successful trial vaccine and reliable factory production.
Historical Significance
Francis's report estimated 80–90 per cent protection against paralytic disease in the more tightly controlled part of the trial. Protection was not uniform: the estimate was 60–70 per cent against type I and at least 90 per cent against types II and III, with relatively few cases making the latter estimates less secure (Francis and Korns 1955).
The headline figure of 1,829,916 children described the U.S. study population, not the number injected. More than 600,000 children completed three injections of vaccine or placebo. The observed-control areas contained 1,080,680 children, most of whom were not injected. Parents, teachers, nurses, doctors, laboratories, local health departments, and hundreds of thousands of lay volunteers made the evaluation possible (Meldrum 1998).
The trial assessed particular lots under controlled conditions. It could not guarantee that every manufacturer would reproduce Salk's formaldehyde-inactivation process. The Cutter incident within weeks of licensing demonstrated that a vaccine's safety depended on filtration, inactivation, lot testing, inspection, and surveillance as much as on its underlying principle (Langmuir, Nathanson, and Hall 1956).
Before the Vaccine
Poliovirus infection and paralytic poliomyelitis are not interchangeable. Most infections produce no recognised illness, while a small proportion invade the nervous system and can cause permanent weakness, paralysis, or death when breathing muscles are affected. The period label “infantile paralysis” was therefore doubly misleading: paralysis was an uncommon outcome of infection, and adolescents and adults could also be affected. This distinction explains why case counts based on clinical disease never measured the full circulation of the virus (World Health Organization).
Large epidemics became conspicuous in northern Europe and North America from the late nineteenth century. Historians and epidemiologists commonly connect that emergence to delayed childhood exposure as sanitation and living conditions changed, but this is a population-level explanation, not a claim that cleanliness itself caused polio. The 1916 epidemic centred on New York and the severe U.S. season of 1952 made paralysis, braces, rehabilitation wards, and mechanical respirators highly visible. Families also encountered quarantines, closed pools, and advice that often outran knowledge about transmission (Oshinsky 2005).
The National Foundation for Infantile Paralysis, established in 1938 under President Franklin D. Roosevelt and Basil O'Connor, paid for care as well as research. Its March of Dimes fundraising relied heavily on images of children with disabilities and on volunteer labour, including the women-led “Mothers' March.” That machinery brought money and attention to polio, but it could also reduce patients to symbols of dependence. Survivors continued to live with disability after incidence fell; prevention did not undo existing paralysis (Oshinsky 2005; Smithsonian National Museum of American History).
Laboratory Path
Failed human vaccine experiments in 1935 had made many virologists wary of both “killed” and weakened live-virus preparations. In 1948, Johns Hopkins virologist Isabel Morgan showed that formalin-inactivated virus could protect monkeys against experimental challenge. Her work did not produce a human vaccine, but it supplied important evidence for an inactivated-virus route (Morgan 1948).
In 1949, John Enders, Thomas Weller, and Frederick Robbins demonstrated that polioviruses could multiply in cultures of non-nervous human tissue. Alongside the recognition that a vaccine needed to cover three immunological virus types, tissue culture made it possible to prepare and test virus in quantities required for a multivalent vaccine (Weller, Robbins, and Enders 1949; Salk et al. 1953).
Salk's laboratory grew the three types in monkey-kidney cell cultures, treated them with formaldehyde, and measured antibody responses. The 1953 preliminary human report named Byron Bennett, L. James Lewis, Elsie Ward, and Julius Youngner with Salk. Its experiments showed an antibody response; they did not yet show protection during natural exposure to polio (Salk et al. 1953).
This distinction corrects two durable myths. Salk did not invent polio research or the idea of inactivation alone, and an antibody response in a small series was not the same evidence as fewer paralytic cases in a field trial. His team's achievement was to turn a dispersed body of virology into a reproducible trivalent vaccine and bring it to population testing.
The 1954 Field Trial
In 84 areas of 11 states, families of 455,474 children requested participation. A coded, double-blind allocation gave a complete three-injection series to 200,745 vaccine recipients and 201,229 placebo recipients. Diagnoses were classified before the code was opened, an important protection against judging a suspected case differently because the child was known to be vaccinated (Francis and Korns 1955).
In 127 areas of 33 states, 221,998 second-grade children completed vaccination, while first- and third-grade children served as principal observed controls. This was easier to administer and avoided placebo injections, but comparison groups were not equivalent. A family survey found differences in income, education, community activity, and access to health conveniences between participants and nonparticipants.
Parents had to request their child's participation, and the National Foundation worked through schools and health departments to recruit them. Children who received injections were publicly called “Polio Pioneers.” Historians treat the trial as both a major exercise in parental permission and public involvement and a product of intense publicity, epidemic fear, and a period before today's research-review and consent systems (Meldrum 1998).
Thomas Francis directed the independent Vaccine Evaluation Center at the University of Michigan; Salk did not analyse his own national trial. The core U.S. programme encompassed 211 study areas in 44 states. Smaller studies in Canada and Finland differed in design and, as the contemporary synopsis acknowledged, produced relatively few cases. Calling all these arrangements one randomised trial conceals the evidential differences within them (Francis and Korns 1955; Marks 2011).
Results and Announcement
In the placebo-control areas, the reported rate of paralytic polio was 16 per 100,000 among fully vaccinated children and 57 per 100,000 among placebo recipients, yielding an overall estimate of 75 per cent under the report's broad paralytic-case definition. The corresponding estimate in the observed areas was 62 per cent. When Francis restricted analysis to more securely diagnosed and laboratory-supported cases, the estimates rose; this is the basis of the widely reported 80–90 per cent figure. The report explicitly said that no single number fully expressed effectiveness (Francis and Korns 1955).
The trial found no significant excess of short-term reactions in vaccine recipients compared with placebo recipients and no evidence that the trial vaccine had caused polio. Francis could therefore describe the tested lots as safe. His report also found no significant difference in non-paralytic disease, however, and noted wide variation in antibody response between lots, particularly for type I. “Safe, effective, and potent,” the phrase in the University of Michigan press release, should be read as a verdict on the study product and the outcomes measured—not an unlimited guarantee about all future manufacture (University of Michigan press release).
The date and presentation amplified the result. The announcement fell ten years after Roosevelt's death, filled the university's Rackham Auditorium with reporters and cameras, and was broadcast to a public that had financed the programme through small donations. Federal licensing on the same day converted a statistical finding into an immediate production and distribution problem (University of Michigan press release; Oshinsky 2005).
The Cutter Incident
Reports of paralysis among children who had received vaccine made by Cutter Laboratories of Berkeley, California, appeared within two weeks of licensing. Cutter vaccine was recalled on 27 April. The surgeon general created a national poliomyelitis surveillance programme on 28 April, and on 7 May recommended suspending vaccination while production plants and testing procedures were inspected. Epidemiology linked certain Cutter lots to residual live type I poliovirus; subsequent investigation identified weaknesses in filtration, inactivation control, safety testing, and federal requirements (Langmuir, Nathanson, and Hall 1956; U.S. Food and Drug Administration).
The contemporary surveillance report had, by 28 October 1955, accepted 204 associated cases and 11 deaths: 79 cases among vaccine recipients, 105 among family contacts, and 20 among community contacts. It classified 158 of the 204 cases as paralytic and warned that its tabulation was not final. Later summaries commonly attribute more than 250 cases to Cutter. The figures are not directly interchangeable: they use different follow-up periods and definitions, and the period report separated people inoculated from those infected after household or community transmission (Langmuir, Nathanson, and Hall 1956; Centers for Disease Control and Prevention).
Vaccination resumed after revised production and review procedures were put in place. The incident did not show that inactivated vaccination was inherently incapable of working; it showed that incomplete inactivation could turn the manufacturing material into the disease it was meant to prevent. It also exposed the weakness of issuing licences before regulators had demonstrated that multiple factories could consistently meet a robust standard. The resulting inspections, lot review, surveillance, litigation, and tighter requirements made Cutter a regulatory as well as a medical turning point (Offit 2005).
Debate and Adoption
Expert disagreement preceded the trial. Albert Sabin, John Enders, and other virologists questioned whether an inactivated vaccine would generate sufficiently durable immunity and feared that a preparation made from virulent virus might retain infectivity. Salk and his sponsors argued that a virus unable to reproduce offered a safer route if inactivation could be controlled. The Cutter failure strengthened one side of that debate without erasing the field-trial evidence for protection. Historians therefore treat “killed versus live” as a contest over evidence, risk, and programme design, not merely a personal rivalry (Meldrum 1998).
Sabin's live-attenuated strains were tested at very large scale in the Soviet Union in the late 1950s and the oral polio vaccine (OPV) became central to many campaigns in the 1960s. Its ease of administration and ability to limit intestinal transmission favoured mass use. Yet replacement was not uniform: the Netherlands built a successful state-produced IPV programme and retained it; Britain adopted IPV cautiously and later moved to OPV; West Germany's fragmented IPV programme reached few people before a rapid turn to oral vaccine. Supply, health-system organisation, domestic production, confidence after Cutter, and Cold War connections all shaped these choices (Lindner and Blume 2006).
The distinction still matters. IPV and OPV are different tools with different programme uses and risks; present-day combinations depend on local epidemiology. This page does not offer vaccination advice. Its point is historical: the 1955 event began a new phase of control, while later eradication depended on multiple vaccines, surveillance systems, local workers, and repeated access to children far beyond the United States (World Health Organization).
Chronology
Legacy
The Salk vaccine helped bring a rapid decline in paralytic polio wherever programmes secured dependable supply and high coverage. Its importance does not require the claim that Salk worked alone, that the trial was one uniform randomised experiment, or that the announcement ended polio. The record is stronger when laboratory colleagues, earlier investigators, children and parents, volunteers, industrial workers, regulators, and later oral-vaccine programmes remain visible.
The event also changed the politics of medical evidence. A philanthropic organisation could mobilise an experiment at national scale; a university centre could make statistical judgment into a public ceremony; and a factory failure could force the state to build surveillance and production controls around that judgment. For a wider comparison, see the History of Vaccination and the earlier history of smallpox vaccination.
References
American Journal of Hygiene 48, no. 3 (1948): 394–406. DOI: 10.1093/oxfordjournals.aje.a119251. Primary experimental report used to establish what Morgan demonstrated in monkeys, without retrospectively calling it a human vaccine.
Proceedings of the Society for Experimental Biology and Medicine 72, no. 1 (1949): 153–155. DOI: 10.3181/00379727-72-17359. Primary report of poliovirus propagation in non-nervous human tissues; a laboratory prerequisite, not a vaccine claim.
JAMA 151, no. 13 (1953): 1081–1098. DOI: 10.1001/jama.1953.13.1081. The Pittsburgh team's preliminary publication; useful for authorship, preparation, and antibody evidence, but written before field effectiveness was known.
American Journal of the Medical Sciences 229, no. 6 (1955): 603–612. DOI: 10.1097/00000441-195506000-00001. Contemporary synopsis of the Vaccine Evaluation Center report, documenting the two study designs, population totals, case classification, reaction data, effectiveness ranges, and acknowledged limitations.
Press release, 12 April 1955, reproduced by the University of Michigan School of Public Health. A contemporary publicity source for the announcement setting and the phrase “safe, effective, and potent.” It translated the technical report for news media and is not treated as an independent scientific evaluation.
BMJ 317, no. 7167 (1998): 1233–1236. DOI: 10.1136/bmj.317.7167.1233. Peer-reviewed historical analysis of the observed and placebo protocols, debate over controls, parental permission, National Foundation publicity, and volunteer organisation.
Clinical Trials 8, no. 2 (2011): 224–234. DOI: 10.1177/1740774511399110. A history-of-medicine reassessment of experimental design, independent evaluation, participating children, and the public institutions behind the trial.
American Journal of Public Health 46, no. 1 (1956): 75–88. Contemporary Public Health Service report. It documents how surveillance was organised, states its case definitions and cut-off dates, and separates Cutter-associated cases among vaccinees, family contacts, and community contacts.
Medical History 50, no. 4 (2006): 425–446. DOI: 10.1017/S0025727300010279. Comparative history showing that health-system structure, production, supply, confidence, and politics produced different national paths from IPV to OPV.
New Haven: Yale University Press, 2005. ISBN 978-0-300-10864-4. A documented reconstruction of manufacturing, regulation, victims, litigation, and the incident's longer institutional consequences.
New York: Oxford University Press, 2005. ISBN 978-0-19-515294-4. A broad social and political history of U.S. epidemics, rehabilitation, the March of Dimes, Salk and Sabin, Cutter, and survivors; useful context beyond the 12 April event.
Museum exhibition record and collections pathway centred on patient experience, medical technologies, community activism, survivors, vaccine development, and the social legacy of polio.
Official institutional history used for the pre-existing federal biologics framework, the 7 May 1955 suspension, plant inspections, review of safety procedures, and the later regulatory significance attributed to Cutter.
Current federal summary used only to show the later “over 250” Cutter attribution and the resumption of vaccination after increased oversight; the 1956 surveillance article provides the period figures.
Fact sheet updated 2 April 2025. Used sparingly for present-day distinctions between infection and paralytic disease, the continuing roles of IPV and OPV, and the unfinished global eradication context.